Bli medlem
Bli medlem

Du är här


Biocartis Group NV: Biocartis announces 2016 half-year results on 6 September 2016


Tuesday, 30 August 2016, 07:00 CEST


Mechelen, Belgium
,30 August 20
16 -
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular
diagnostics company (Euronext Brussels: BCART), today announces that it will
report its half-year 2016 results and outlook for the remainder of the year
on 6 September 2016 at 07:00h CEST.

The Biocartis management team will host a conference call with live webcast
presentation on the day of the results announcement, on 6 September 2016 at
14:00h CEST / 13:00h BST (UK) / 08:00h EDT (US). The live webcast can be
accessedhere. If you would like to participate in the questions and answers
session, please dial in 5-10 minutes prior to the start time using the
numbers below and confirmation code 6014209.

Participants, New York, US: +1 646 254 3362

Participants, London, UK: +44 (0)20 3427

Participants, Paris, France: +33 (0)1 76
77 22 28

Participants, Amsterdam, Netherlands: +31 (0)20 716 8295

Participants, Brussels, Belgium: +32 (0)2 404

The conference call and webcast will be conducted in English. A replay of the
webcast will be available on theBiocartis investors websiteshortly after.

--- END ---

More information:

Renate Degrave
Manager Corporate Communications&Investor Relations
tel +32 15 631 729

mobile +32 471 53 60 64

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has five oncology tests and two infectious disease tests on the market. More
information: Press Photo Library availablehere. Follow us
onTwitter: @Biocartis_.

Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company or, as appropriate, the Company
directors' current expectations and projections concerning future events such
as the Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in which the
Company operates. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that could
cause actual results or events to differ materially from those expressed or
implied by the forward-looking statements. These risks, uncertainties,
assumptions and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition and technology,
can cause actual events, performance or results to differ significantly from
any anticipated development. Forward-looking statements contained in this
press release regarding past trends or activities are not guarantees of
future performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even if
actual results or developments are consistent with the forward-looking
statements contained in this press release, those results or developments may
not be indicative of results or developments in future periods. As a result,
the Company expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or representatives
nor any of its subsidiary undertakings or any such person's officers or
employees guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any responsibility for
the future accuracy of the forward-looking statements contained in this press
release or the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak only as
of the date of this press release.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.